US antidepressant users face growing risk of post‑SSRI sexual dysfunction

Selective serotonin reuptake inhibitors (SSRIs) now account for about 70% of antidepressant prescriptions in the United States, with tens of millions of people taking them daily. From 2006 to 2023, the number of children and adolescents aged 3‑17 receiving SSRIs more than doubled. A growing concern is post‑SSRI sexual dysfunction (PSSD), a condition that can cause loss of libido, pleasure‑less orgasms, genital numbness and emotional blunting, persisting even after the medication is stopped.

Despite these risks, there is no federal requirement for psychiatrists to disclose PSSD to patients, and the FDA does not mandate a warning label for the condition. Many prescriptions are now issued through brief telehealth visits or AI‑driven chatbots, often without detailed discussion of sexual side effects. Studies show that among 1,473 patients on citalopram, 54% reported decreased libido, 36% difficulty achieving orgasm, and 37% of men experienced erectile dysfunction. The lack of regulatory warnings and the ease of prescribing raise public‑health concerns about informed consent and long‑term sexual health outcomes.